Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.43 |
| ▸ | ANPEP | P15144 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3345460 | 0.95 | MMP2 (0.45) | MMP2ANPEPHTTNPC1CYP3A4 | |
| SCHEMBL2148264 | 0.95 | MMP2 (0.45) | MMP2ANPEPHTTNPC1CYP3A4 | |
| SCHEMBL18657109 | 0.95 | MMP2 (0.45) | MMP2ANPEPHTTNPC1CYP3A4 | |
| SCHEMBL2297429 | 0.94 | MMP2 (0.44) | MMP2ANPEPHTTNPC1CYP3A4 | |
| SCHEMBL14685401 | 0.94 | MMP2 (0.44) | MMP2ANPEPHTTNPC1CYP3A4 | |
| SCHEMBL19657862 | 0.92 | MEN1 (0.42) | MMP2ANPEPNPC1CYP3A4MEN1 | |
| SCHEMBL12284558 | 0.91 | ANPEP (0.50) | MMP2ANPEPHTTNPC1CYP3A4 | |
| SCHEMBL1121964 | 0.91 | ANPEP (0.50) | MMP2ANPEPHTTNPC1CYP3A4 | |
| SCHEMBL5926169 | 0.90 | ANPEP (0.41) | MMP2ANPEPHTTNPC1CYP3A4 | |
| SCHEMBL13512916 | 0.90 | ANPEP (0.41) | MMP2ANPEPHTTNPC1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191309-A1 | Pyrrolobenzodiazepines as key intermediates in the synthesis of dimeric cytotoxic pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191309-A1 | Pyrrolobenzodiazepines as key intermediates in the synthesis of dimeric cytotoxic pyrrolobenzodiazepines | CBR3, CBR1, CYCS | MMP2 4274/4885ANPEP 4349/4885HTT 1605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.